Incannex partners with AASM to sponsor research grant
By HME News Staff
Updated 11:15 AM CDT, Thu March 26, 2026
MELBOURNE and NEW YORK – Incannex Healthcare has joined the American Academy of Sleep Medicine (AASM) Foundation’s Corporate Recognition Program and will sponsor a Focused Projects Grant for Junior Investigators dedicated to the diagnosis, management and treatment of sleep apnea to be awarded in 2026. Incannex says the partnership reflects its commitment to the broader sleep medicine community as it continues to advance IHL-42X, its lead investigational oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea (OSA). “Obstructive sleep apnea is a serious, chronic condition that remains substantially undertreated – and for too many patients, existing options are simply not sufficient,” said Dr. Luigi Barbato, MD, chief medical officer. “IHL-42X is designed to address that unmet need, and this partnership with the AASM Foundation reflects our deep commitment to the broader scientific community working to change that. Supporting the next generation of sleep medicine researchers is something we are genuinely proud to do, and we look forward to contributing to the advancement of the field alongside our own clinical program.” Incannex says the past year has been one of the most productive in its history, marked by a series of meaningful milestones, including positive Phase 2 clinical trial results that demonstrated statistically significant improvements in OSA outcomes, providing strong validation of IHL-42X's therapeutic potential and setting a compelling foundation.
Comments